Back

The role of TAK1 inhibition in doxorubicin-induced cardiotoxicity: an in vitro study

30 August 2025 (16:15 - 17:00)
Organised by: Logo
Congress Presentation Part of: Cardio-oncology and therapy Cancer Biology and Treatment ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Associate Professor Bertha Polegato

Faculty of Medicine of Botucatu, UNESP, Botucatu (Brazil)

3 More presentations in this session

Presentation thumbnail
NLRP3/IL-1 pathway was reduced by semaglutide and dapagliflozin in association therapy under exposure to anthracyclines in hyperglycemic conditions
Doctor N. Maurea (Naples, IT)
Abstract Slides Video
Presentation thumbnail
Age- and sex-specific association between clonal hematopoiesis of indeterminate potential and pulmonary hypertension
Doctor G. Sun (Guangzhou, CN)
Abstract Slides Video
Presentation thumbnail
Variability in echocardiographic surveillance for cardiotoxicity in HER2+ versus HER2- breast cancer: a SEER-medicare analysis
Associate Professor J. Strom (Boston, US)
Abstract Slides Video

Access the full session

Session thumbnail
Cardio-oncology and therapy

The Event

Event poster

ESC Congress 2025

30 August 2025 16:15 CET
You may be interested in
thumbnail
Congress Presentation
Modulation of p300 acetylation to protect against doxorubicin-induced cardiotoxicity
thumbnail
Congress Presentation
Deciphering doxorubicin-induced cardiotoxicity:insights at single-cell resolution
thumbnail
Congress Presentation
Sodium-glucose cotransporter 2 inhibitor Dapagliflozin reduces systemic H-FABP and monocyte-to-lymphocyte ratio in preclinical models of antracycline induced cardiotoxicity

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources